Philosophy Capital Management LLC Makes New $6.05 Million Investment in Orthofix Medical Inc. $OFIX

Key Points

• Philosophy Capital Management LLC acquired 370,763 shares of Orthofix Medical Inc., valued at approximately $6,047,000, increasing its stake to about 0.95% of the company.
• Several institutional investors have significantly increased their stakes in Orthofix Medical, with Juniper Investment Company LLC raising its holdings by 123.5% in the last quarter.
• Orthofix Medical received a "strong-buy" rating from Barrington Research, with an average price target set at $21.50 by analysts.

Philosophy Capital Management LLC acquired a new position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 370,763 shares of the medical device company's stock, valued at approximately $6,047,000. Philosophy Capital Management LLC owned 0.95% of Orthofix Medical as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of OFIX. Juniper Investment Company LLC boosted its holdings in shares of Orthofix Medical by 123.5% during the fourth quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company's stock valued at $33,824,000 after acquiring an additional 1,070,656 shares during the period. Engine Capital Management LP boosted its position in shares of Orthofix Medical by 8.4% during the 1st quarter. Engine Capital Management LP now owns 3,741,390 shares of the medical device company's stock valued at $61,022,000 after purchasing an additional 290,646 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Orthofix Medical by 31.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company's stock valued at $11,515,000 after buying an additional 159,177 shares in the last quarter. Nuveen LLC acquired a new position in shares of Orthofix Medical in the 1st quarter worth $1,445,000. Finally, Soleus Capital Management L.P. raised its position in shares of Orthofix Medical by 13.1% during the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company's stock worth $11,984,000 after purchasing an additional 79,441 shares during the period. Institutional investors own 89.76% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research report on Friday, June 6th. Wall Street Zen upgraded Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Barrington Research upgraded Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective on the stock in a report on Monday, June 23rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $21.50.

Insider Activity

In related news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the completion of the sale, the insider directly owned 46,322 shares of the company's stock, valued at $486,844.22. The trade was a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is owned by corporate insiders.

Orthofix Medical Trading Down 0.6%

OFIX traded down $0.09 during mid-day trading on Tuesday, reaching $14.61. The stock had a trading volume of 306,257 shares, compared to its average volume of 471,007. The stock has a market capitalization of $576.95 million, a P/E ratio of -4.61 and a beta of 0.86. Orthofix Medical Inc. has a 52 week low of $10.24 and a 52 week high of $20.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67. The firm's fifty day simple moving average is $12.68 and its two-hundred day simple moving average is $13.30.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. The business had revenue of $203.12 million during the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities analysts predict that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.